Ovarian cancer biomarker could predict treatment response and help prevent metastasis

A research team from Case Western Reserve University in Ohio discovered a new microRNA biomarker, miR-181a, that may identify patients who will respond better to treatment for ovarian cancer and could serve as a drug target to prevent metastasis. Ovarian tumors are more likely to be resistant to chemotherapy with high levels of miR-181a, which in turn promotes metastasis by …

Guest post: Redefining cancer may change the orphan status of cancer drugs

      *This post was originally posted on the Context Matters blog* Context Matters will be exhibiting at Evidence USA this October in Boston.  Join us at America's largest and most holistic event on the use of real world outcomes for pharmaceutical products.   A recent NY Times piece by Tara Parker-Pope reported on the recommendation by a group …